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1.0 INTRODUCTION 
The liver diseases have become one of the major causes of morbidity and 
mortality all over world. From among, drug induced liver injury (DILI) is one of the 
most common causative factor that poses a major clinical and regulatory challenge. 
The manifestations of drug-induced hepatotoxicity are highly variable, ranging from 
asymptomatic elevation of liver enzymes to fulminate hepatic failure. Paracetamol 
(PCM) also known as Acetaminophen, taken in overdose can cause severe 
hepatotoxicity and nephrotoxicity. PCM is activated and converted by cytochrome 
P450 enzymes to toxic metabolite NAPQI (N-acetyl-p-benzoquinoneimine) that 
causes oxidative stress and glutathione (GSH) depletion. In spite of tremendous 
advances in modem medicine, there are hardly any reliable drugs that protect the 
liver from damage and/or help in regeneration of hepatic cell. Many active plant 
extracts are frequently utilized to treat a wide variety of clinical diseases including 
liver disease. Therefore, searching for effective and safe drugs for liver disorders are 
continues to be an area of interest. Aegle mameloes, belongs to family Rutaceae is 
commonly known as beal. It exhibits contraceptive, hypoglycemic activity, cardio 
protective effects and anti-hyperlipidaemic activity. Aloe vera (family-Liliaceae) has 
been reported to have antifungal activity, hypoglycemic activity, anti- inflammatory, 
anticancer, immunomodulatory, gastro- protective and anti-hepatotoxic properties1-5. 
Eclipta alba (family-Asteraceae) commonly known as Bringraj, has been shown to 
posses anti- inflammatory, anti-hypertensive, anti-hepatotoxic, immunomodulatory, 
anthelmintic, expectorant. 
Hepatic diseases are a major worldwide health problem, with frequently 
found in developing countries. They are mainly caused by uses of high doses of 
chemicals and some drugs. There is no effective drug available that stimulates liver 
function, offer protection to the liver from damage or help to regenerate hepatic 
cells. Therefore there is urgent need, for effective drugs to replace/add those in 
current use. Medicinal herbs are significant source of pharmaceutical drugs. Latest 
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trends have shown increasing demand of phytoconstituents from some medicinal 
herbs and those medicinal herbs have proven hepatotprotective potential.A numbers 
of herbal preparations are available in the market. The present review is aimed at 
compiling data on promising phytochemicals from medicinal plants that have been 
tested in hepatotoxicity models using modern scientific system. In this century 
clinical research has confirmed the efficacy of  some herbs in the treatment of liver 
related disease. Hence, this review article contributes to the knowledge of reported 
indigenous plants, which are prevalent for prevention and treatment ofliver 
disorders6-9. 
The liver has more functions than any other human organ and also is a 
largest part of the body. The blood supply passes through the liver several times a 
day. The Liver has a important role in human metabolism. Liver produces and 
secretes bile, it also produces prothrombin and fibrinogen, both blood clotting 
factors, and heparin. It converts sugar into glycogen. Liver diseases have become 
one of the major causes of morbidity and mortality in man and animals. 
Hepatotoxicity due to drugs appears to be the most common factor. The most 
common disease that can affect the liver is 'viral hepatitis'. Hepatitis mainly caused 
by drugs, viruses, bacteria, parasites like amoebas or giardiasis. The use of natural 
remedies to treat the liver diseases has a long history. There are some medicinal 
plants and their derivatives which still used all over the world in one form or the 
other, have been tested and found to contain active principles with curative 
properties against a variety of diseases. Hepatoprotective plants contain a variety of 
chemical constituents like phenols, coumarins, lignans, essential oil, monoterpenes, 
carotinoids, glycosides, flavanoids, organic acids, lipids, alkaloids and xanthenes. 
Recent experience has shown that plant drugs are non-toxic, safe and even free from 
side effects. 
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There are many plants and traditional formulations available to treat the liver 
diseases. About 600 commercial herbal formulations with hepatoprotective activity 
are being sold all over the world.  
Around 170 phytoconstituents isolated from 110 plants belonging to 55 
families have been reported to possess hepatoprotective activity. In India, more than 
93 medicinal plants are used in different combinations in the preparations of 40 
patented herbal formulations. However, only a small proportion of hepatoprotective 
plants as well as formulations used in traditional medicine are pharmacologically 
evaluated. 
Table No. 1: Herbs having hepatoprotective activity 
S. 
No. 
Biological name 
Common 
name 
Extract 
1. 
Andrographis lineatanees 
(Acanthaceae) 
Kirayat, 
Kalamegha 
Methanol and aqueous 
extract 
2. 
Azadirachta indica 
(Meliaceae) 
Neem Methanolic extract 
3. 
Careya arborea 
(Myrtaceae) 
Kumbhi, slow 
match tree 
Methanolic extract 
4. Cassia fistula(fabaceae) Amaltas Methanolic extract 
5. 
Cleome viscosalinn 
(Capparidaceae) 
Tickweed Ethanolic extract 
6. Eclipta alba(Asteraceae) Bhringaraj Ethanol:water 1:1 extract 
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S. 
No. 
Biological name 
Common 
name 
Extract 
7. 
Fumaria 
indica(Fumariceae) 
Hauskn 
Petroleum ether extract 
against CCl4, methanolic 
extract against 
rifampicine, and aqueous 
extract against PCM. 
8. 
Morinda citrifoliaLinn 
(Rubiaceae) 
Noni 
Ethanol extract 
 
9. 
Phyllanthus 
amarus(Euphorbiaceae) 
Bhuiamala Ethanolic extract 
10. 
Phyllanthus 
emblica(Euphorbiaceae) 
Amla Ethanolic extract 
11. 
Phyllanthus 
polyphyllus(Euphorbiaceae) 
Dalzell Methanolic extract 
12. 
Phyllanthus 
reticulates(Euphorbiaceae) 
Potato bush Ethanolic extract 
13. 
Picrorhiza 
kurroa(Scrophulariaceae) 
Kutki Alcoholic extract 
14. 
Polygala 
arvensis(Polygalaceae) 
Field milkwort Chloroform extract 
15. 
Pterocarpus 
santalinus(Fabaceae) 
Kanak champa 
Aqueous and ethanol 
extract 
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S. 
No. 
Biological name 
Common 
name 
Extract 
16. 
Ptrospermum 
acerifolium(Sterculiaceae) 
Maple-leaved 
Bayur tree 
Ethanol extract 
17. 
Solanum 
nigrum(Solanaceae) 
Makoi 
Ethanol extract 
18. 
Cichorium 
intybus(Asteraceae) 
Kasni 
Ethanol extract 
19. 
Swertia 
chirata(Gentianaceae) 
Chirayata 
Ethanol extract 
20. 
Wedelia calendulaceaLinn 
(Asteraceae) 
Bhanra Ethanolic extract 
21. 
Anoectochilus 
formosanus(Orchidaseae) Jewel Orchid Aqueous extract 
23. 
Ixora coccineaLinn 
(Rubiaceae) 
Thetchi Aqueous extract 
 
1.1 Pathophysiological Mechanisms 
Pathophysiological mechanisms of hepatotoxicity are still being discovered 
and comprise both hepatocellular/extracellular mechanisms.  
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1.2 Disruption of hepatocyte 
Medications can bound to intracellular proteins by covalent tying which 
bring about a lessening in ATP levels prompting actin interruption. Part of actin 
fibrils at the surface of the hepatocyte causes blebs and burst of the layer. 
1.3 Disruption of transport protein 
Bile stream may be interrupted by medications that influence transport 
proteins at canalicular film. Loss of villous procedures and intrusion of transport 
pumps, for example, multidrug resistance- related protein 3 forestall discharge of 
bilirubin bringing about cholestasis 
1.4 Cytolytic T-cell activation 
 Co-valent tying of medication to Cytochrom P-450 enzyme goes about as an 
immunogen activating T-cells and cytokines and animating multifaceted immune 
reactions.  
1.5 Apoptosis of hepatocytes 
Enhancement of apoptotic pathways by tumor necrosis factor-alpha receptor 
of Fas may trigger the course of intercellular caspases, which bring about 
customized cell death. 
1.6 Mitochondrial disruption:   
A few medications restrain mitochondrial capacity by double impact on both 
beta- oxidation energy productions by hindering the synthesis of nicotinamide 
adenine dinucleotide and flavin adenine dinucleotide, bringing about diminished 
ATP generation. 
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1.7 Bile duct injury 
Dangerous metabolites disposed of in bile may bring about harm to bile 
conduit epithelium10. 
1.8 Drug Induced Hepatotoxicity 
Medication/drug prompted liver damage is a well-being issue, and is relied 
upon to increment as the quantity of medications being devoured increments, both 
prescription and non-prescription, and because of the present pattern of utilization of 
pharmacologically active substances in complementary and alternative medicine. 
Medication/drug prompted hepatotoxicity is the most well-known reason referred for 
withdrawal of officially approved medications from the business. It additionally 
represents more than 50 percent of instances of intense liver failure in the United 
States. The definite frequency of medication/drug prompted liver damage is hard to 
gauge, and all in all, studies going to measuring its occurrence experience the ill 
effects of disadvantages, for example, under-reporting and that information by large 
originate from review studies. Regularly, there is likewise an absence of data about 
self-solution and utilization of herbal product that may interact with medicine and 
non-physician endorsed medications11-13.  
Notwithstanding the recurrence of medication instigated liver damage being 
low, information from the Centers for Disease Control and Prevention in the U.S. 
report more or less 1600 new intense instances of liver failure yearly, of which 
Paracetamol hepatotoxicity represents give or take 41%. At the point when taking a 
gender at hospitalized patients, the rate of antagonistic medication responses is 
evaluated to be 6.7%, and lethal unfriendly medication responses add up to 0.32%, 
as controlled by a meta-analysis of around 40 prospective studies. During the period 
1995 to 2005, the reports of unfavorable medication responses and additionally 
deaths identified with these, have dramatically multiplied. Numerous instances of 
medication triggered liver damage are idiosyncratic, i.e. the response is capricious 
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taking into account the known pharmacological properties of the drug, and 
henceforth is barely noticeable during preclinical phases of improvement. There are 
however studies to show that these responses may be subject to an expanded 
affectability of the patient to the medication being referred to, contingent upon such 
components as other accompanying infections or other corresponding medications. 
Certain hereditary variables, for example, HLA-type, can now and again add to the 
affectability of a person to antagonistic medication responses. Ordinarily, clinically 
clear unfriendly medication responses happen when some time of idleness, anyplace 
in the compass going from one to 12 months (most generally inside of 90 days), and 
about dependably vanish after evacuation of the medication. Medication investigated 
liver harm may give a few distinctive clinical components; hepatitis /hepatocellular, 
cholestatic or mixed. 
Despite their etiology, medication/drug induced hepatotoxicity remains a 
noteworthy issue during medication development in the pharmaceutical industry, 
both concerning expanded danger for patients experiencing clinical trials, 
furthermore patient-risk after the introduction of new medication to the treatment. 
Additionally, due to the expanded expenses that take after failure of a medication to-
be at a late stage in medication development or after its launch. 
1.9 Drug Toxicity Mechanisms 
Typical division of medication reactions is of not less than 2 noteworthy 
gatherings which include: 
 Drugs which straightforwardly influence liver.  
 Drugs which intercede an immune reaction. 
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1.10 Intrinsic / predictable drug reactions 
Drugs that belongs into this classification cause reproducible wounds in 
animals and harm is identified with dose. Harm can be because of medication itself 
or to its metabolite. Acetaminophen is the most appropriate illustration of a known 
natural or unsurprising hepatotoxin at super therapeutic dosages. Another illustration 
is carbon tetrachloride. 
1.11 Idiosyncratic/unpredictable drug reactions 
 These drug responses can be segmented into those that are classified as 
hypersensitivity or immunoallergic and those that are metabolic-idiosyncratic. It 
happens without obvious.  
 
Figure No. 1:  Risk factors for hepatotoxicity 
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Figure No. 2: Three-step mechanistic working model of hepatotoxicity 
Hepatotoxicity largely indicates the chemical compelled liver destruction. Some 
medications when consumed in overdose and occasionally even when taken within 
recommend dose may damage many internal organs. Few compound/substances 
comprising those that are used in laboratories (Example: CCl4 and Paracetamol) and 
industries (Lead, and arsenic) and natural compounds (microcystine and aflatoxins) 
and herbal therapies (cascara sagrada, ephedra) can root hepatotoxicity. 
Chemicals/Compounds that cause liver damage are branded as hepatotoxins14-21. 
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 NSAIDS (Acetaminophen, Aspirin, Ibuprofen) 
 Glucocorticoids.  
 Anti-Tubercular drug (Isoniazid). 
 Industrial toxins (arsenic, carbon tetrachloride, vinyl chloride). 
 Herbal remedies (Ackee fruit, camphor, cycasin, kava leaves, valerian, 
comfrey). 
1.12 Alcohol Hepatotoxicity  
Alcohol is one of the fundamental inducer of end-stage liver damage around 
the world. In the United States, alcoholic liver disease is the second most regular 
purpose behind liver transplantation. The Dionysos Study, a cohort investigation of 
the predominance of ceaseless liver disease in an Italian populace, demonstrated that 
21% of the populace considered was at danger for creating liver damage. Of these, 
just 5.5% of the people at danger hinted at real liver damage. Around 50 years prior 
it was accepted that alcohol in itself was not harmful, rather that the dietary 
inadequacies frequently going hand in hand with it were the real reasons for liver 
harm. In any case, it was indicated by Lieber and De Carli that in rats, alcoholic liver 
damage created in spite of adequate sustenance. The lethality of alcohol was later on 
demonstrated to be identified with its digestion system by alcohol dehydrogenases 
(ADHs) furthermore to the digestion system by CYP2E1. There is additionally a 
part of digestion system by catalase. The fundamental pathway for ethanol (EtOH) 
oxidation in the liver is by means of ADH to acetaldehyde, which is connected with 
the reduction of NAD to NADH. NADH thus builds xanthine oxidase action, which 
rises generation of superoxide. Metabolic system of EtOH by alcohol dehydrogenase 
impacts the redox status of the liver likewise in different ways. Elevated 
acetaldehyde creation after EtOH metabolism diminishes hepatic glutathione (GSH) 
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content. The diminishing in GSH is both because of an expanded misfortune, and 
also a lower rate of synthesis  
 
Figure No. 3: Alcohol Hepatotoxicity – Mechanism 
 
 
Figure No. 4: Alcohol Hepatotoxicity – Disease Progression 
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Ethanol induces number of deleterious metabolic changes in liver. Intake of 
ethanol for long time leads to development of steatosis, alcoholic hepatitis and 
cirrhosis resulting in weight and volume changes. About 80% of heavy drinkers had 
been reported to develop steatosis, 10-35% alcoholic hepatitis and approximately 
10% liver cirrhosis. 
1.13 Mechanism underlying Ethanol induced hepatotoxicity 
Alcohol consumption results in increase in release of endotoxin from gut 
bacteria and membrane permeability of gut to endotoxin or both. Females are more 
often sensitive to these changes. Blood endotoxin is elevated and enters liver where 
it is engulfed by Kupffer cells that become activated releasing TNF- alpha, PGE2 
and free radical. Prostaglandins increase oxygen uptake and are responsible for 
hypermetabolic state in liver. Increase in oxygen demand leads to hypoxia of liver 
and on reperfusion alpha - hydroxyethyl free radicals are formed that leads to tissue 
damage in oxygen poor pericentral regions of liver lobule. Blocking of these events 
can be done by sterilization of gut using antibiotics or destruction of Kupffer cells 
with Gdcl3 and thus prevents liver injury. 
.  
Figure No. 5: Mechanism of ethanol induced hepatotoxicity 
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1.14 Symptoms of Hepatotoxicity 
List of signs and symptoms depicted in various causes for Hepatotoxicity 
include 15 symptoms as listed below: 
 Nausea 
 Vomiting 
 Abdominal pain 
 Loss of appetite 
 Diarrhea 
 Tiredness 
 Weakness 
 Jaundice 
 Yellow eyes 
 Yellow skin 
 Hepatomegally 
 Abnormal liver function test results 
 Swelling in feet 
 Weight gain due to water retention 
 Prolonged bleeding time. 
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1.15 Treatment for Hepatotoxicity 
The list of treatments mentioned in various sources for hepatotoxicity 
includes the following. Always follow professional medical advice about any 
treatment or change in treatment plans. Treatment of hepatotoxicity is depends upon 
causative agent, degree of liver dysfunction and age and general health of patient. 
Treatments for hepatotoxicity include: 
 Withdrawal of causative medication or removal from exposure to causative 
agent. 
 Regular monitoring of patient and review of liver function – where liver 
dysfunction is mild to moderate and liver function is improving. 
 Complete avoidance of alcohol and medication that may contribute to further 
liver damage. 
 N-Acetylcysteine is used for paracetamol toxicity. 
 Management of symptoms of liver damage. 
 Nutrition – with vitamin supplementation as required 
 Regular exercise in order to maintain muscle mass. 
 Ursodeoxycholic acid. 
 Management of pruritus 
 Cholestyramine 
 Antihistamines. 
 Management of ascites 
 Low sodium diet. 
Chapter – 1  Introduction 
Department of Pharmacology 16            J.K.K. Nattraja College of Pharmacy 
 Diuretics – furosemide, spironolactone. 
 Removal of fluid via a needle in the abdomen – Paracentesis.   
 Portosystemic shunting. 
  Management of portal hypertension 
 Beta – blockers 
 Oesophageal variceal banding 
 Portocaval shunt 
 Management of acute liver failure due to hepatotoxicity 
 Supportive care always in intensive care unit – airway protection, 
fluid and electrolyte management. 
 Management of complications such as bleeding problems and hepatic 
encephalopathy.    
 Liver transplantation – for acute fulminant liver failure or end stage cirrhosis. 
1.16 Modern Medicines for Treatment of Liver Diseases 
Liver diseases can be treated using allopathic as well as by using herbal 
drugs. 
1.17 Hepatoprotective Allopathic Treatment 
Few modern medicines are available for treating liver diseases that includes: 
 Ursodeoxycholic acid (Ursodiol): Ursodiol decreases intestinal absorption 
and suppresses hepatic synthesis and storage of cholesterol. It is mainly used 
in management of chronic hepatic diseases in humans. 
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 Penicillamine: Penicillamine chelates several metals like copper, iron, lead 
and mercury forming stable water soluble complexes which are renally 
excreted22-28. 
Other drugs: 
Antiviral medication such as alpha interferon, ribavirin, steroids, antibiotics 
etc. are also used in liver diseases. Drugs like tricholinecitrate, trithioparamethoxy 
phenyl propane, essential phospholipids, combination of drugs such as L-ornithine, 
L-aspartate and pancreatin, silymarin and Ursodeoxycholic acid are usually 
prescribed for hepatitis, cirrhosis and other liver diseases. N-acetylcysteine is used in 
early phases of acetaminophen toxicity. L-carnitine is potentially valuable during 
valproate toxicity. Cholestyramine can be used to alleviate pruritus. 
1.18 Disadvantages of allopathic drugs 
Side effects of many modern medicines are mostly alarming. Interactions, 
contra-interactions, side effects and toxicity of synthetic medicine vary from mild to 
severe that includes insomnia, vomiting, fatigue, dry mouth, diarrhea, constipation, 
dizziness, suicidal thought, depression, seizures, anemia, hair loss, high blood sugar, 
swelling, impotency, confusion, fainting and finally death. Antibiotics usually cause 
stomach upset or allergic reactions. Interferon shows side effects as flu-like illness 
with fever and body aches29. 
1.19 Herbal Hepatoprotective Drug Treatment 
A number of polyherbal preparations have been used in treating various liver 
disorders since ages. Some herbal formulations include: 
a) Liv-52: It is a non-toxic hepatoprotective drug from Himalaya Drug Co. Liv-
52 can improve clinical parameters in patients having liver damage mainly in 
alcoholic liver cirrhosis. 
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b) LIMARIN®: It has potent hepatoprotective and free radical scavenging 
(antioxidant) activity. It is derived from active extract of fruit of silybum 
marianum. 
Some of the polyherbal formulations have been evidenced for 
hepatoprotective activity against chemical driven liver damage in 
experimental animals which include Liv52, Liv42, Jigrine, Koflet, Cirrhitin, 
Livex and Hepatomed10 etc.  
1.20 Limitations of herbal preparations 
Herbal- based preparations for treating liver disorders has been used in India for 
long time and has been popularized worldwide by leading pharmaceuticals. Despite 
of popularity of herbal medicines for liver diseases in particular, are still 
unacceptable treatment modalities for liver diseases. Limiting factors include: 
 Lack of standardization procedures of herbal preparations. 
 Lack of identification of active components and principles. 
 Lack of randomized controlled clinical trials (RCTs). 
 Lack of toxicological evaluation67. 
 Poor solubility. 
 Poor bioavailability. 
 Poor hepatic cell regeneration30,31.  
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2.0 LITERATURE REVIEW 
Marklund S, et al., (2011)32 evaluated the hepatoprotective activity of Andrographis 
paniculata in ethanol induced hepatotoxicity in albino rats. In the study the aqueous 
extract of A. paniculata (50mg/kg, 100mg/kg, 200mg/kg body weight) was found to 
protect the lever from hepatotoxic action of ethanol by significant reduction in the 
transaminase level. 
Martin P,  et al., (2008) 33aimed to find out the hepatoprotective activity of 
Orthosiphon stamineus on liver damage caused by paracetamol in rats. The 
methanolic extract of leaves in the dose of 100mg and 200mg/kg body weight was 
given to the rats affected by paracetamol and investigated and found that the extract 
showed siginificant recovery and suggested that O. stamineus methanol leaf extract 
possessed hepatoprotective activity.  
Muriel P, et al., (2011)34 studied the hepatoprotective active of Mimosa pudica 
Linn. In carbon tetrachloride indued hepatotoxicity in rats. Mimosa pudica Linn. Is 
commonly used herbs against many disease. The hydroalcoholic extract of dried 
powder of whole plant was investigated in CCl4 hepatotoxicity rats modle at the 
dose of 200mg/kg, 400mg/kg and 800mg/kg body weight and found recovery in the 
liver function biochemical parameters. Histology of liver sections of animals treated 
with extract showed the hepatic cell regeneration. The results support the 
hepatoprotective effect of Mimosa pudica Linn. 
Nkosi CZ,  et al., (2005)35 investigated hepatoprotective activity of aqueous extract 
of Lawsonia lnermis against paracetamol induced rats. The aqueous extract of 
Lawsonia lnermis was administered orally to the animals with hepatotoxicity 
induced by paracetamol. Silymarin was was given as reference standard. The plant 
aqueous extract was found to be effective in protecting the liver against the injury 
induced by paracetamol in rats. The result proved the hepatoprotective activity of 
Lawsonia lnermis agsinst paracetamol induced rats. 
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Okokon JE,  et al., (2007)37 studied the hepatoprotective activity of Dregea volubilis 
fruit against paracetamol induced liver damage in rats. The liver of the rats was 
affected with paracetamol and the damaged liver were treated with the extract in 
dose of 100mg/kg and 200mg/kg body weight and sylimerin 25mg/kg body weight 
was also given as reference standard and compaired the different liver function test 
and found safe recovery of the treated group. The results concluded that the Dregea 
volubilis fruit has hepatoprotective activity. 
Plaa GL, et al., (2006)38 studied on preparation of quercetin solid lipid nanoparticles 
and oral absorption in mice model. In this study nanoparticles were prepared by 
emulsion evaporation at a high temperature and solidification method at low 
temperature. Result shows QT-SLN morphology was sphere like and smooth in 
nature. Mean diameter was 217.3nm. Entrapment efficiency was 48.50%. The mice 
oral absorption of QT-SLN was much better than quercetin solution. 
Prakash J, et al., ( 2001)39 discussed the various techniques for the fabrication of 
nano drug delivery system (NDDS) like nanoparticles, nanocrystals, 
nanosuspension, and nanoemulsions by various techniques such as bottom-up 
(Microprecipitation, microemulsion and melt emulsification) top –down method 
(High pressure homogenization and milling method). 
Reitman S, et al., (2012)40produced small anionic polymeric (Eudragit) 
nanoparticles containing quercetin in a non-crystalline form. They proved that after 
mouth stomach and small intestine stages the amount of quercetin released was 
around 43%,16% and 7% for free quercetin dispersed in water and around 5%, 3%, 
2% of quercetin encapsulated within polymeric nanoparticles. These results 
suggested that nanoparticles protected quercetin from dissolution in mouth and 
stomach but promoted its release in small intestine. 
Setzer WN, et al., (2007)41 prepared quercetin-loaded nanoparticles with gelation of 
chitosan with tripolyphosphate anions poly-D, L- lactide (PLA) nanoparticles by 
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solvent evaporation method inorder to improve aqueous solubility and stability of 
quercetin. Nano-encapsulation of quercetin into PLA nanoparticles significantly 
improves therapeutic efficacy and bioavailability of this molecule. The in vitro 
release studies showed that 40-45% quercetin was released within 0-0.5h showing 
rapid burst release. 
Shahank T, et al., (2011)42 Carried out the physicochemical characterization of 
nanoparticles using different methods like transmission electron microscopy (TEM), 
differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), Fourier 
transform infrared spectroscopy (FT-IR) and dissolution study. Particle size 
determination, encapsulation efficiency, drug release and SEM studies have also 
been used for characterization of nanoparticles. 
Streeter AJ, et al., (2008)43 developed quercetin loaded- nanoparticles (QUEN) by 
nanoprecipitation technique with Eudragit E (EE) and polyvinyalcohol (PVA) as 
carriers and to evaluate antioxidant effects of quercetin (QU) and its nanoparticles. 
Results from powder X-ray diffraction (XRD) and differential scanning calorimetry 
(DSC) of QUEN showed that crystal of drug might be converted to an amorphous 
state. Release of drug from QUEN was 74- fold higher compared with pure drug. In 
addition antioxidant activity of QUEN was more effective than pure QU. 
Hussain MA, et al., (2014)44 performed Intracellular ROS protection efficiency and 
free radical-scavenging activity of quercetin and quercetin-encapsulated 
liposomes.this study indicated that liposomal quercetin can significantly improve the 
solubility and bioavailability of quercetin and can be used as an effective antioxidant 
for ROS protection within the polar cytoplasm, and the nano-sized quercetin 
encapsulated by liposomes enhanced the cellular uptake (cancer cell human 
MCF_7). Quercetin has many pharmaceutical applications, many of which arise 
from its potent antioxidant properties. 
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Zakaria ZA, et al., (2014)45 developed Quercetin-containing self-nanoemulsifying 
drug delivery system for improving oral bioavailability Q-SNEDDS formed a 
nanoemulsion having a droplet size of 208.8 ± 4.5 nm and zeta potential of -26.3 ± 
1.2 mV. The presence of Tween® 80 and PEG 400 increased quercetin solubility 
and maintained supersaturated quercetin concentrations (5 mg/mL) for >1 month. 
The optimized Q-SNEDDS significantly improved quercetin transport across a 
human colon carcinoma (Caco-2) cell monolayer. Fluorescence imaging 
demonstrated rapid absorption of the Q-SNEDDS within 40 min of oral ingestion. 
Following oral administration of Q-SNEDDS in rats (15 mg/kg), the area under the 
concentration curve and maximum concentration of plasma quercetin after 24 h 
increased by approximately twofold and threefold compared with the quercetin 
control suspension. These data suggest that this Q-SNEDDS formulation can 
enhance the solubility and oral bioavailability of quercetin for appropriate clinical 
application. 
Mukherjee PK, et al.,  (2013)46formulated and optimized the topical delivery of 
quercetin from solid lipid based nanosystems. In this research work, a solvent-free 
solid lipid based nanosystem has been developed and evaluated for topical delivery 
of quercetin. Systematic screening of the formulation and process parameters led to 
the development of a solid lipid (glyceryl dibehenate) based nanosystem using a 
probe ultrasonication method. The selected variant demonstrated good physical 
stability for up to 8 weeks at 2-8 °C. Transmission electron microscopy (TEM) 
images showed spherical particles in the nanometer range. In vitro release studies 
showed biphasic release of quercetin from the SLN formulation, with an initial burst 
release followed by prolonged release for up to 24h. In vitro permeation studies 
using full thickness human skin showed higher amounts of quercetin to be localized 
within the skin compared to a control formulation with particles in the micrometer 
range. Such accumulation of quercetin in the skin is highly desirable since the 
efficacy of quercetin in delaying ultra-violet radiation mediated cell damage and 
eventual necrosis mainly occurs in the epidermis. 
Chapter – 2  Literature Review 
Department of Pharmacology 23            J.K.K. Nattraja College of Pharmacy 
Panda S, et al., (2012)47 studied Anticancer effect and mechanism of polymer 
micelle-encapsulated quercetin on ovarian cancer. In this work, encapsulated QU 
into biodegradable monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) 
(MPEG-PCL) micelles and tried to provide proof-of-principle for treating ovarian 
cancer with this nano-formulation of quercetin. These QU loaded MPEG-PCL 
(QU/MPEG-PCL) micelles with drug loading of 6.9% had a mean particle size of 36 
nm, rendering the complete dispersion of quercetin in water. QU inhibited the 
growth of A2780S ovarian cancer cells on a dose dependent manner in vitro. 
Intravenous administration of QU/MPEG-PCL micelles significantly suppressed the 
growth of established xenograft A2780S ovarian tumors through causing cancer cell 
apoptosis and inhibiting angiogenesis in vivo. Furthermore, the anticancer activity of 
quercetin on ovarian cancer cells was studied in vitro. Quercetin treatment induced 
the apoptosis of A2780S cells associated with activating caspase-3 and caspase-9. 
MCL-1 downregulation, Bcl-2 downregulation, Bax upregulation and mitochondrial 
transmembrane potential change were observed, suggesting that quercetin may 
induce apoptosis of A2780S cells through the mitochondrial apoptotic pathway. 
Otherwise, quercetin treatment decreased phosphorylated p44/42 mitogen-activated 
protein kinase and phosphorylated Akt, contributing to inhibition of A2780S cell 
proliferation. This data suggested that QU/MPEG-PCL micelles were a novel nano-
formulation of quercetin with a potential clinical application in ovarian cancer 
therapy. 
Jatwa R, et al., (2013) 48developed A transdermal delivery system to enhance 
quercetin nanoparticle permeability . A quercetin nanoemulsion was prepared using 
poly(lactic-co-glycolic acid) (PLGA), hyaluronic acid (HA) and emulsifier (Tween-
20) through a solvent evaporation technique. The efficiency of the nanoemulsion 
was evaluated with and without chemical permeation enhancer (CPE). The FT-IR 
result shows no interaction between quercetin and polymer that proves excellent 
compatibility. The transdermal delivery ability was evaluated using in vitro release 
and ex vivo permeation analysis. The transdermal drug-release mechanism was 
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studied by the mathematical model and was found to obey a zero-order, diffusion-
controlled mechanism. In vitro toxicity and cell behavior, including cell adhesion, 
proliferation and cell death of quercetin-nanoemulsion-treated L929 cells.The 
produced nanoemulsion showed a high encapsulation efficiency, less toxicity, 
controlled delivery with enhanced transdermal drug permeation and effective 
scavenging of free radicals. 
Murugan M, et al., (2013)49 performed a Long-term stability of quercetin 
nanocrystals prepared by different methods. Quercetin nanocrystals were prepared 
by high pressure homogenization, bead milling and cavi-precipitation. The 
nanocrystals produced by these methods were compared for particle size, saturation 
solubility and dissolution of the drug particles, and were subjected to stability 
testing. Key finding of this study the X-ray diffraction study and microscopic 
pictures taken under polarized light indicated the crystalline nature of the 
nanocrystals produced by the three methods. As the crystalline state is relatively 
more stable than the amorphous state, a good physical stability was expected from 
the quercetin nanocrystals prepared. The high-pressure homogenized and bead-
milled quercetin nanocrystals showed excellent physical stability when stored under 
refrigeration (4±2°C) and at room temperature (25±2°C) for 180 days. The 
dissolution properties were not significantly affected on storage at room 
temperature. However, increase in the storage temperature to 40±2°C led to physical 
instability. On the other hand, the cavi-precipitated quercetin nanocrystals exhibited 
a lower stability than the bead-milled and homogenized formulations and did not 
show the optimum zeta potential values as well. In the case of cavi-precipitated 
nanocrystals, recrystallization and agglomeration were responsible for the increasing 
particle size besides the Ostwald ripening phenomenon. The solvents used during 
cavi-precipitation might have competed with the surfactant for hydration leading to a 
partial dehydration of the surfactant, which subsequently affected the stability of the 
quercetin nanocrystals.This study concluded that High-pressure homogenized and 
bead-milled quercetin nanocrystals showed better physical stability than the cavi-
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precipitated ones. Freeze drying immediately after nanocrystal production can help 
to prevent their agglomeration and thus improve physical stability. 
Boonphong S,  et al., (2010)50 Design and characterization of protein-quercetin 
bioactive nanoparticles. Induced by dimethyl sulfoxide (DMSO), BSA, Lys, and Mb 
formed spherical nanocarriers with sizes less than 70 nm. After loading Q, the size 
was further reduced by 30%. The adsorption of Q on protein is mainly hydrophobic, 
and is related to the synergy of Trp residues with the molecular environment of the 
proteins. Seven Q molecules could be entrapped by one Lys molecule, 9 by one Mb, 
and 11 by one BSA. The controlled releasing measurements indicate that these 
bioactive nanoparticles have long-term antioxidant protection effects on the activity 
of Q in both acidic and neutral conditions. The antioxidant activity evaluation 
indicates that the activity of Q is not hindered by the formation of protein 
nanoparticles. Other flavonoids, such as kaempferol and rutin, were also 
investigated. These studies conclude the BSA exhibits the most remarkable abilities 
of loading, controlled release, and antioxidant protection of active drugs, indicating 
that such type of bionanoparticles is very promising in the field of 
bionanotechnology. 
Lakshmi BVS, et al., (2009)51 performed the Development of a quercetin-loaded 
nanostructured lipid carrier formulation for topical delivery. QT-NLCs were 
prepared by the method of emulsion evaporation-solidification at low temperature. 
The average entrapment efficiency and drug loading of the optimized QT-NLCs 
were 89.95 ± 0.16% and 3.05 ± 0.01%, respectively. Under the transmission electron 
microscope, the nanoparticles were spherically shaped. The average particle size 
was 215.2 nm, the zeta potential was -20.10 ± 1.22 mV and pH value of QT-NLCs 
system was 4.65. Topical delivery of QT in the form of NLCs was investigated in 
vitro and in vivo. The results showed that QT-NLCs could promote the permeation 
of QT, increase the amount of QT retention in epidermis and dermis, and enhance 
the effect of anti-oxidation and anti-inflammation exerted by QT. Then the 
Chapter – 2  Literature Review 
Department of Pharmacology 26            J.K.K. Nattraja College of Pharmacy 
mechanism of NLCs for facilitating drug penetration was further investigated 
through histological sections. In conclusion, NLCs could be a promising vehicle for 
topical delivery of QT. 
Anand KV,  et al., (2010)52 formulated oral active nanomicellar of quercetin in the 
treatment of lung cancer. Quercetin-loaded nanomicelles were prepared by using the 
film casting method, and were evaluated in terms of drug incorporation efficiency, 
micelle size, interaction with Caco-2 cells, and anticancer activity in the A549 lung 
cancer cell line and murine xenograft model. In this study result shows that the 
incorporation efficiency into the nanomicelles was ≥88.9% when the content of 
quercetin was up to 4% w/w, with sizes of 15.4-18.5 nm and polydispersity indices 
of <0.250. Solubilization of quercetin by the nanomicelles increased its aqueous 
concentration by 110-fold. The quercetin nanomicelles were stable when tested in 
simulated gastric (pH 1.2) and intestinal (pH 7.4) fluids, and were non-toxic to the 
Caco-2 cells as reflected by reversible reduction in transepithelial electrical 
resistance and ≤25% lactose dehydrogenase release. The anticancer activity of 
quercetin could be significantly improved over the free drug through the 
nanomicellar formulation when tested using the A549 cancer cell line and murine 
xenograft model. The nanomicellar quercetin formulation was well tolerated by the 
tumor-bearing animals, with no significant weight loss observed at the end of the 10-
week study period. Concluded that a stable PEG-PE nanomicellar formulation of 
quercetin was developed with enhanced per oral anticancer activity and no apparent 
toxicity to the intestinal epithelium. 
Annegowda HV, et al., (2012)53  Development of biodegradable nanoparticles for 
delivery of quercetin. The antioxidant molecule quercetin has been encapsulated on 
poly-D,L-lactide (PLA) nanoparticles by solvent evaporation method for the 
improvement of its poor aqueous solubility and stability. The result shows that 
surface morphology and average size of PLA and quercetin loaded PLA 
nanoparticles are 170+/-25 and 130+/-30 nm respectively. The antioxidant activities 
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of the PLA encapsulated quercetin nanomedicine are identical to free quercetin. The 
nanoencapsulation efficiency of quercetin evaluated by HPLC and antioxidant assay 
is 96.7%. The in vitro release kinetics under physiological condition show initial 
burst release followed by slow and sustained release. The complete release and 
maximum retention of quercetin is 72 and 96h respectively. The less fluorescence 
quenching efficiency of quercetin-PLA nanoparticles than free quercetin on BSA 
confirms the controlled release of quercetin from PLA nanoparticles. These 
properties of PLA encapsulated quercetin molecule pave way for encapsulating 
various therapeutically less useful highly active antioxidant molecules towards the 
development of better therapeutic compounds. 
Nagi BS, et al ., (2008)54 prepared Dual agents loaded PLGA nanoparticles: 
systematic study of particle size and drug entrapment efficiency.PLGA nanoparticles 
simultaneously loaded with vincristine sulfate (VCR) and quercetin (QC) were 
prepared via O/W emulsion solvent evaporation. Six independent processing 
parameters and PLGA characteristics were assessed systematically to enhance the 
incorporation of the dual agents with different properties (VCR and QC, hydrophilic 
and hydrophobic molecule, respectively) into PLGA nanoparticles and control 
particle size. Approaches investigated for the enhancement of drug entrapment 
efficiencies and the controlling of particle size included the influence of the 
molecular weight (MW) of PLGA and the lactide-to-glycolide (L:G) ratio of PLGA, 
PLGA concentration, PVA concentration, initial QC content, acetone-to-
dichloromethane (A/D) volume ratio, aqueous phase pH and aqueous to organic 
phase (W/O) volume ratio. The nanoparticles produced by optimal formulation were 
submicron size (139.5+/-4.3 nm, n=3) with low polydispersity index (0.095+/-0.031, 
n=3). Nanoparticles observed by transmission electron microscopy (TEM) showed 
extremely spherical shape. The entrapment efficiencies determined by high 
performance liquid chromatography (HPLC) by ultracentrifuge method were 
92.84+/-3.37% for VCR and 32.66+/-2.92% for QC (n=3). The drug loadings were 
0.0037+/-0.0001% for VCR and 1.36+/-0.12% for QC (n=3). 
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Fang EF, et al., (2009)55 developed quercetin by solid lipid nanoparticles that 
Enhance gastrointestinal absorption. The aim of the present study is to design and 
characterize quercetin-loaded solid lipid nanoparticles (QT-SLNs), clarify the 
absorption mechanism of QT-SLNs and to evaluate the potential of using solid lipid 
nanoparticles (SLNs) as an oral delivery carrier for poorly water soluble drugs. QT-
SLNs were prepared by an emulsification and low-temperature solidification 
method. The QT-SLNs presented as spherically shaped under transmission electron 
microscopy, with an average diameter of 155.3 nm. The average drug entrapment 
efficiency, drug loading and zeta potential were 91.1%, 13.2% and -32.2 mV, 
respectively. Drug release from QT-SLNs was fitted to a double phase kinetics 
model and the equation was as follows: 100-Q=98.87e(-0.1042t)+42.45e(-0.0258t). 
The absorption of QT-SLNs in the gastrointestinal (GI) tract was studied using an in 
situ perfusion method in rats. It was found that the absorption percent in the stomach 
for 2 h was only 6.20%, the absorption process of intestine was first-process with 
passive diffusion mechanism, and the main absorptive segments were ileum and 
colon. A pharmacokinetic study was conducted in rats after oral administration of 
quercetin at 50 mg/kg in the form of either QT-SLNs or suspension. The plasma 
concentration-time curves were both fitted to a one-compartment model. The 
relative bioavailability of QT-SLNs to quercetin suspension was 571.4%. The 
T(max) and MRT for quercetin in plasma were both delayed. Our studies provide 
evidence that SLNs are valuable as an oral delivery carrier to enhance the absorption 
of a poorly water soluble drug, quercetin. 
 Naravana KR, et al., (2013)56 developed the Co-encapsulation of tamoxifen and 
quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor 
efficacy, and drug-induced toxicity. The developed formulation was found to have 
particle size 185.3 ± 1.20 nm, PDI 0.184 ± 0.004, entrapment efficiency 67.16 ± 
1.24% Tmx, 68.60 ± 1.58% QT at a Tmx/QT ratio of 1:2 w/w. The stability of the 
freeze-dried formulation was established in simulated gastrointestinal fluids for 8 h 
and at accelerated stability condition for 3 months. DPPH free radical scavenging 
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assay confirmed that the functional architecture of QT was retained in freeze-dried 
NPs. Higher cellular uptake, cytotoxicity, and nuclear co-localization of Tmx-QT-
NPs in MCF-7 cells revealed higher efficiency of the formulation. At the same time, 
higher Caco-2 cell uptake revealed its potential for oral delivery, which was well 
corroborated with in vivo pharmacokinetics, which suggested ∼ 5-fold and ∼ 3-fold 
increase in oral bioavailability as compared to the free Tmx citrate and free QT, 
respectively. Concomitantly, significantly higher tumor suppression was observed in 
the case of the developed formulation in contrast to respective free drug(s) and their 
combination when tested against a DMBA-induced breast cancer model in female 
SD rats. Multiple oral administrations of Tmx-QT-NPs efficiently controlled the 
tumor angiogenesis as revealed by normalized levels of respective markers (MMP-2 
and MMP-9). The safety profile of Tmx-QT-NPs was also established, and no 
measurable hepatotoxicity or oxidative stress was observed when measured as a 
function of respective biochemical markers in contrast to free drug(s) and their 
combinations. In a nutshell, the co-encapsulation strategy with PLGA-NPs could be 
a promising approach in improving oral delivery of Tmx and QT for cancer therapy. 
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3.0. PLANT PROFILE 
                  
 
KINGDOM      : Plantae  
CLADE             : Angiosperms 
ORDER             : Gentianales 
FAMILY           : Rubiaceae 
GENUS             : Ixora 
TAMIL NAME : Vetchi  
            Fig. No. 6:  Leaves of Ixora chenensis 
Ixora is a large genus of about 400 species of popular evergreen shrubs and 
small trees, many of which are native to southern china, India and Srilanka and 
belong to the taxonomic family rubiaceae. A few of these species are grown in 
gardens for  their vibrantly coloured flowers  produced in large clusters at  the  tips 
of  branches. Various  species of Ixora  are otherwise called as  West Indian  
Jasmine , Jungle Flame , Flame  of the  World , Jungle Geranium etc., but are very 
popular by the genus name, Ixora. 
CHARACTERISTICS: 
Ixora is a compact, multibranched evergreen shrubs or small tree, commonly 
4 to 6 feet in height, but can reach up to 12 feet height. Leaves are glossy, leathery, 
oblong, about 4 to 6 inches long and are arranged in opposite pairs. 
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PHYTOCHEMICAL CONSTITUENTS : 
* D- Mannitol 
* Stearic acid 
* 1,5-Cyclooctadiene 
* Beta-Sitosterol 
* Azelaic acid 
* Dihydromasticadienolic acid 
* Ixoraliphatic acid 
 
MEDICINAL USES : 
A decoction of the root is used after child birth. A decoction is used against 
bronchial disorders. An infusion of the fresh flowers is said to be a remedy against 
incipient tuberculosis and haemorrhage. A decoction is prescribed in the treatment 
of amenorrhoea and hypertension. An infusion of leaves or flowers is used against 
headache.   
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4.0 AIM & OBJECTIVE 
Herbal drugs play a vital role in the management of various liver disorder, 
most of them speed up the natural healing process of liver. Numerous medicinal 
plants and their formulations are used in liver disorders in ethno medicinal practices 
as well as traditional system of medicine in India. According to WHO about 18,000 
people die every year due to hepatic disease. Liver diseases remain one of the 
serious health problems is the absence of variable liver protective drugs. The 
common ailments of liver are cirrhosis, cholestasis, hepatitis, portal hypertension, 
hepatic encephalopathy, hepatic failure and certain tomours like hepatoma. 
 The aim of the research is to find out new hepatoprotective drugs from 
indigenous plants which are potent and nontoxic agents.. Present study deals with 
the hepatoprotective activity leaves of Ixora chenensis.  
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5.0 PLAN OF THE WORK 
 To investigate the organoleptic and morphological characteristics of Ixora 
chenensis leaves to establish the pharmacognostical standards of the plants.  
  To carry out preliminary phytochemical analysis of extracts of leaves of 
Ixora chenensis to establish the different classes of compounds present their 
leaves.  
 To evaluate the extracts of Ixora chenensis leaves for antioxidant activity by 
different radical scavenging methods and methods based on reducing ability 
of extracts.   
 To evaluate the extracts of Ixora chenensis for acute toxicity potential and 
establish their margin of therapeutic safety. 
 To evaluate the hepatoprotective activity of extracts of Ixora chenensis 
leaves against carbon tetrachloride induced liver damage in rats. 
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6.0 MATERIALS AND METHODS 
6.1 Plant collection and authentification 
The leaves of Ixora chenensis were collected from Kolli forest area, 
Tamilnadu and which was authenticated.  
6.2 Preparation of coarse powder and Extraction technique 
The leaves were shade dried at room temperature for 10 days. Then these 
were milled into powder by mechanical grinder. This powder was sequentially 
extracted to their increasing polarity with Petroleum ether, Ethyl acetate, Ethanol 
respectively. About 500gm of powdered leaves was uniformly packed into a thimble 
in a soxhlet apparatus and extracted with 1000ml Petroleum ether, Ethyl acetate and 
Ethanol, respectively. Constant heat was provided by Mantox heater for recycling of 
the solvent. The process of extraction continues for 1-2 hours for each solvent. The 
excess solvent was evaporated and the dried extracts were kept in refrigerator at 4ºC 
for their future use in phytochemical analysis and pharmacological screenings. 
6.3 Phytochemical Analysis 
6.3.1 Test for carbohydrates 
 Molisch’s test: Dissolved small quantity of 300mg alcoholic and dried leaves 
extract powder of Pimenta dioica separately in 4ml distilled water and 
filtered. The filtrate was subjected to Molisch’s test.  
 Fehling’s test: Dissolve a small portion of extract in water and treat with 
Fehling’s solution. 
 Phenols test: The extract was spotted on a filter paper. A drop of 
phosphomolybdic acid reagent was added to the spot and was exposed to 
ammonia vapours. 
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6.3.2 Test for flavanoids  
 Shinoda test: To 2 to 3ml of extract, a piece of magnesium ribbon and 1ml of 
concentrated HCl was added . 
 .Lead acetate test: To 5ml of extract 1ml of lead acetate solution was added.  
6.3.3 Test for tannins 
 Braemer’s test: To a 2 to 3ml of extract, 10% alcoholic ferric chloride 
solution was added. 
6.3.4 Test for steroid/terpenoid 
 Liebermann-Burchardt test: To 1ml of extract, 1ml of chloroform, 2 to3ml of 
acetic anhydride and 1 to 2 drops of concentrated Sulphuric acid are added. 
6.3.5 Test for alkaloids 
 Draggendorf’s test: A drop of extract was spotted on a small piece of 
precoated TLC plate and the plate was sprayed with modified Draggendorf’s 
reagent.  
 Hager’s test: The extract was treated with few ml of Hager’s reagen. 
 Wagner’s test: The extract was treated with few ml of Wagner’s reagent. 
6.3.6 Tests for Glycosides 
 Legal’s test: Dissolved the extract [0.1g] in pyridine [2ml], added sodium 
nitroprusside solution [2ml] and made alkaline with Sodium hydroxide 
solution. 
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6.3.7 Test for Saponins 
 Foam test: 1ml of extract was dilute with 20ml of distilled water and shaken 
with a graduated cylinder for 15 minutes. 
6.3.8 Test for Anthraquinones 
 Borntrager’s test: About 50 mg of powdered extract was heated with 10% 
ferric chloride solution and 1ml of concentrated HCl. The extract was cooled, 
filtered and the filtrate was shaken with diethyl ether. The ether extract was further 
extracted with strong ammonia. 
6.3.9 Test for Amino acids 
 Ninhydrin test: Dissolved a small quantity of the extract in few ml of water 
and added 1ml of ninhydrin reagent. 
6.3.10 Test for fixed oils and fats 
 Press small quantity of the petroleum ether extract between two filter paper. 
Note: the results for the above experiments can be noted as follows. 
 If the response to the test is high it can be noted as +++which indicates that 
the particular group is present as the major class. 
 If the response is average then note it as ++ indicates the presence in 
moderate quantity. 
 If the response is very small then note it as + indicating the presence of only 
in traces. 
 If no response is then negative. 
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6.4 Pharmacological screenings 
6.4.0 Invitro Antioxidant activity 
6.4.1 Reducing power by Ferric Chloride(FRAP) 
 The standard stock solution was prepared by dissolving ascorbic acid (Standard 
Sample) in suitable solvent (methanol) with a final concentration of 1000 µg/ml 
and different concentration of 100, 200, 300, 400, 500 µg/ml were prepared by 
distilled water. 
 About 100 mg of Ixora chenensis extract were dissolved in 100 ml of methanol 
to obtain a solution of 1000µg/ml. From this stocking solutions, various working 
conc. were produced to get concentration of 100, 200, 300, 400, 500 µg/ml with 
distilled water. 
 About 1.5 milliter of 10 percentage tri-chloro aceticacid was then dropped to the  
mixture and the contents were centrifuged at 3000 rpm for 10 minutes and about 
1.5 ml of supernatant liquid was collected and mixed with 1 ml of distilled water 
and 0.5 ml of 1 % FeCl3.  
 The absorbance noted at seven hundred nanometer using UV-Visible 
Spectrophotometer.Difference in the absorbance between test and control was 
calculated and expressed as reducing power in percentage.95-104 
 Ability of reducing power of test and control in percentage was calculated by 
following formula:  
 
 All experimentsdone three times. 
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6.4.2 DPPH assay 
 0.3mM DPPH solution was prepared by dissolving DPPH (5.91mg) in 50 ml of 
methanol.This stock solution was prepared freshly and kept in the dark at 
ambient temperature when not in used. 
 The standard stock solution was prepared by dissolving ascorbic acid (Standard 
Sample) in suitable solvent (methanol) with a final concentration of 1000 µg/ml 
and different concentration of 100, 200, 300, 400, 500 µg/ml were prepared by 
distilled water. 
 About 100 mg of Ixora chenensisextract were dissolved in 100 ml of methanol 
to obtain a solution of 1000µg/ml. From this stocking solutions, various working 
conc. were produced to get concentration of 100, 200, 300, 400, 500 µg/ml with 
distilled water. 
 The standard stock solution was prepared by dissolving ascorbic acid (Standard 
Sample) in suitable solvent (methanol) with a final concentration of 1000 µg/ml 
and different concentration of 100, 200, 300, 400, 500 µg/ml were prepared by 
distilled water. 
 0.3 mM solution of free radical standard in CH3OH produced and 1 ml of this 
solution was admixed to three milliliter of test solution in water at various 
different conc and kept for 30 minutes, the absorbance was taken at 517nm.  
Difference between the absorbance value of sample and control of (DPPH) was 
obtained and given as percent scavenging of free radical.95-104 
 
 All experimentswere performed in triplicate. 
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6.4.3 ABTS+ Radical Scavenging Assay 
 The standard stock solution was prepared by dissolving ascorbic acid 
(Standard Sample) in suitable solvent (methanol) with a final concentration 
of 1000 µg/ml and different concentration of 100, 200, 300, 400, 500 µg/ml 
were prepared by distilled water. 
 About 100 mg of Ixora chenensisextract were dissolved in 100 ml of 
methanol to obtain a solution of 1000µg/ml. From this stocking solutions, 
various working conc. were produced to get concentration of 100, 200, 300, 
400, 500 µg/ml with distilled water. 
 The standard stock solution was prepared by dissolving ascorbic acid 
(Standard Sample) in suitable solvent (methanol) with a final concentration 
of 1000 µg/ml and different concentration of 100, 200, 300, 400, 500 µg/ml 
were prepared by distilled water. 
 ABTS+ radical was freshly prepared by adding 5 ml of 4.9 nM ammonium 
persulfate solution to 5ml of 14 mM ABTS solution and kept for 16 hrs in 
the dark ambience. Resultant solution was dispersed with ethyl alcohol (99.5 
percentages) to gained value of 0.700 ± 0.020 at 734 nanometer and the 
similar was utilized for assay purpose. 
 About 950µl of ABTS radical solution has been added with 50 microliter of 
sample or referrals solution and the reaction mixture was vortexed for 10 sec 
and kept for 6 minutes. 
 The absorbance was recorded at 734 nm compared with the manage ABTS. 
%age suppression was calculated from following formula. 95-104 
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 All experimentswere performed in triplicate. 
6.4.4 Nitric Oxide Scavenging Method 
 The standard stock solution was prepared by dissolving ascorbic acid 
(Standard Sample) in suitable solvent (methanol) with a final concentration 
of 1000 µg/ml and different concentration of 100, 200, 300, 400, 500 µg/ml 
were prepared by distilled water. 
 About 100 mg of Ixora chenensisextract were dissolved in 100 ml of 
methanol to obtain a solution of 1000µg/ml. From this stocking solutions, 
various working conc. were produced to get concentration of 100, 200, 300, 
400, 500 µg/ml with distilled water. 
 The standard stock solution was prepared by dissolving ascorbic acid 
(Standard Sample) in suitable solvent (methanol) with a final concentration 
of 1000 µg/ml and different concentration of 100, 200, 300, 400, 500 µg/ml 
were prepared by distilled water. 
 Sodium nitroprusside 5mM in phosphate buffer at pH 7.4 saline was added 
with a range of concentrations of the test sample or standard and incubated at 
25oC for 150 minutes. At regular intervals, 1.5 ml of samples (incubated test 
sample) were taken off and a poured with 1.5 ml Griess reagent (1% 
Sulphanilamide, phosphoric acid (2 percent), and 0.1 percent NEDA 2.HCL. 
 The absorbance was read at 540 nm.The difference in the absorbance 
between test and control on nitric oxide was determined and depicted as 
percent scavenging of NO radical. 95-104 
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 Capability to scavenge the NO radical was designed by using formulas. 
 
 All experiments were performed in triplicate. 
6.5 Acute Oral Toxicity Study  
Acute toxicity study was carried using albino rats by up and down/staircase 
method as per OECD guidelines. The methanolic extract of Ixora chenensis Linn. 
(MEIC) was orally administered to different groups of rats at the doses of 50, 300, 
1000, 2000 and 3000 mg/kg body weight, respectively. The animals were observed 
for 48 hr to study the general behavior and for any sign of discomfort to the animals. 
There was no mortality found upto dose 3000 mg/kg. 
6.6 In-vivo Hepatoprotective Activity of Ixora chenensis Leaves Extract in 
CCL4 Induced Liver Damage in Wistar Rats  
Wistar rats (150-200grams) of Male sex were used in the study and were 
obtained from the Animal house, JKKNCP, Kumarapalayam. The studies were 
performed with the approved by the institutional animal ethical committee, and 
these animals were used to evaluate Hepatoprotective activity of Ixora 
chenensis leaves extract. Prior to the experiment the rats were housed in a clean 
poly propylenecages (6rats/cages) for a period of 7 days under standard 
temperature (25-30o c), relative humidity (45–55%), dark/lightcycle (12/12hrs). 
The animals were put in overnight fasting were deprived of food for 16 hrs but 
allowed free access of water. 
  
Chapter – 6  Materials and Methods 
Department of Pharmacology 42            J.K.K. Nattraja College of Pharmacy 
6.6.1 Chemicals Required 
 Carbon Tetra Chloride, Standard Liver Tonic (silymerin), Leaves extract of 
Ixora chenensis. 
6.6.2 Animals Required 
 Species/common name : wistar rats 
 Age/weight/size  : 3 months/180- 200 gms 
 Gender   : male 
Number of animals to be used: 6 nos 
Number of days each animal will be housed in 60 days  
6.6.3 Experimental Design 
The animals will divided into 4 groups of 6 rats in each.  
Group-I- Positive control 
Group-II- CCl4 (Carbon tetra chloride) will given intra peritonially (1ml/ kg) with 
1:1 dilution of coconut oil on the 5thday.  
Group-III- Administered with liver tonic marketed product (5ml/kg) daily for 7 
days and on 5th day the CCl4 is induced through intra peritonially (1 ml / kg). 
Group-IV- Was treated with alocoholic extract of Ixora chenensis high dose for 7 
days, CCl4 is administered on day 5. On the 8th day, all rats will be sacrificed and 
the blood collected, centrifuged and the collected serum samples will studied for 
Serum glutamate oxaloacetate transaminase (SGOT), Serum glutamate pyruvate 
transaminase (SGPT) and bilirubin (through kits) tests for the study of the toxic 
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effect of CCl4 and also the therapeutic effect of the plant extracts. The livers will 
fixed in the fixative (Bouin’s fluid) for the histological study. 
6.6.4 Collection of serum  
Fasting blood samples were drawn from tail vein of rats at weekly intervals 
till the end of the study 5, 7, and 8 days. 
6.6.5 Estimation of biochemical parameters Serum  
On5, 7, and8 days fasting blood samples were collected and analyzed the  
serum levels. 
6.6.6 Statistical analysis 
Statistical analysis was done by using GRAPH PAD PRISM 5.0.  All the 
values of Biochemical parameters and body weight were expressed as Mean ± 
Standard Error Mean (SEM). The values were analyzed for statistical significance 
using one- way analysis of variance (ANOVA), comparison was done by using 
Dunnett’st test. P values < 0.05 were considered as significant, P values < 0.01were 
considered as very significant, P values < 0.001 were considered as highly 
significant and P > 0.05 were considered as not significant.  
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7.0 RESULTS & DISCUSSION 
7.1 Appearance and percentage yield of Extract 
AEIC were a semisolid brownish color extract and the percentage yield was 
found to be 19.35% 
7.2. Phyochemical Analysis 
Below two observations indicated absence of Saponins because not Formed 
stable foam confirmed the test &formation of a soluble emulsion confirmed the test. 
The formation of blue colour in acetic acid layer confirmed the test.  Formed red 
color was formed in test tube in the presence of glycosides. 
 The phytochemical screening results revealed that the after which it was 
observed whether the alkaloids were present by the indication of turbidity and/or 
precipitate formation. The colour changed from violet to blue or green in some 
samples indicated the presence of steroids. An interface with a reddish brown 
coloration was formed in the presence of terpenoids, as positive result. Red 
coloration identifies the presence of flavonoids (Shinado’s test). A colour change 
was observed in the test tube, which indicated in the presence of tannins. A brown 
ring formation at the junction and the turning of the upper layer to dark green color 
confirmed the test for the absence of phytosterols. Some o the test indicated no 
characteristic changes on test tube by the absence of fixed oil, liginin and gum 
mucilage. 
  
Chapter – 7  Results & Discussion 
Department of Pharmacology 45            J.K.K. Nattraja College of Pharmacy 
Table No. 2: Phytochemical screening of the leaf Ixora chinensis 
S.No Constituents Methanol 
1 Alkaloids + 
2 Carbohydrates + 
3 Glycosides + 
4 Phytosterol - 
5 Fixed oil - 
6 Saponins - 
7 Tannins + 
8 Proteins & amino 
acids 
+ 
9 Gum & mucilage - 
10 Flavonoids + 
11 Lignin - 
 
Invitro antioxidant 
The extracts was showed similar increasing trend in activity with increase in 
extract concentration. There was a strong correlation FRAP values supporting the 
fact will that phenolics and flavonoids are highly potent antioxidants. 
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Table No. 3: Invitro antioxidant activity byferric Chloride method (FRAP) 
S.No. Concentration 
(µg/ml) 
Leaf extract Standard 
(Ascorbic acid) 
1.  100 27.08± 0.42 40.96 ± 0.24 
2.  200 33.05± 0.18 52.50 ± 0.27 
3.  300 40.05 ± 0.35 65.51 ± 0.34 
4.  400 51.03 ± 0.96 77.14 ± 0.65 
5.  500 67.28± 0.67 88.26 ± 0.48 
 
 
Figure No. 7: Ferric chloride Method- Leaf extract 
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Figure No. 8: Ferric chloride Method- Standard (Ascorbic acid) 
Invitro antioxidant (DPPH Assay) 
Extract was demonstrate similar rising trend in activity with augment in 
extract concentration. There was a strong correlation DPPH values supporting the 
fact will that phenolics and flavonoids are highly potent antioxidants. 
Table No. 4: Invitro antioxidant activity byDPPH Assay 
S.No. Concentration 
(µg/ml) 
Leaf extract Standard 
(Ascorbic acid) 
1.  100 58.26 ± 0.39  63.60 ± 0.68 
2.  200 59.18 ± 0.29 67.10 ± 0.52 
3.  300 60.30 ± 0.61 73.23 ± 0.46 
4.  400 61.23 ± 0.23 77.00 ± 0.56 
5.  500 71.52± 0.28 84.30 ± 0.36 
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Figure No. 9: DPPH- Leaf extract 
 
 
 
Figure No. 10: DPPH- Leaf extract 
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In vitro Antioxidant (ABTS+) 
Extract was representative alike rising tendency in activity with enhance in 
extract concentration. There was a strong correlation ABTS+ values supporting the 
fact will that phenolics and flavonoids are highly potent antioxidants. 
Table No. 5: In vitro Antioxidant activity by ABTS+ 
S.No. Concentration 
(µg/ml) 
Leaf extract Standard 
(Ascorbic acid) 
1.  100 35.19± 0.48  79.59 ± 0.26 
2.  200 45.32 ± 0.38 84.02 ± 0.52 
3.  300 56.56 ± 0.28 86.79 ± 0.48 
4.  400 61.56 ± 0.26 91.56 ± 0.58 
5.  500 71.28± 0.26  95.44 ± 0.45 
 
 
 
Figure No. 11: DPPH- Leaf extract 
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Figure No. 12: DPPH- Standard (Ascorbic acid) 
In vitro Antioxidant (Nitric Oxide) 
The extracts was showed similar increasing trend in activity with increase in 
extract concentration. There was a strong correlation Nitric Oxide values supporting 
the fact will that phenolics and flavonoids are highly potent antioxidants. 
Table No. 6: In vitro Antioxidant activity by Nitric Oxide Scavenging Method 
S.No. Concentration 
(µg/ml) 
Leaf extract Standard 
(Ascorbic acid) 
1.  100 27.08± 0.42 40.96 ± 0.24 
2.  200 33.05± 0.18 52.50 ± 0.27 
3.  300 40.05 ± 0.35 65.51 ± 0.34 
4.  400 51.03 ± 0.96 77.14 ± 0.65 
5.  500 67.28± 0.67 88.26 ± 0.48 
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Figure No. 13: Nitric oxide Scavenging- Leaf extract 
 
 
 
Figure No. 14: Nitric oxide Scavenging- Standard (Ascorbic acid) 
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Invivo Hepatoprotective Studies 
Carbon Tetra Chloride Induced Hepatoprotective Activity 
CCl4 is one of the most powerful Hepatotoxins which is able to induce liver 
damage through the formation of reactive Hepatoprotective activity of Otostegia 
persica in rats. Free radicals such as Trichloromethyl (CCl3) or Trichloroperoxyl 
radicals (CCl3 O°3). It can cause severe damages to the liver such as fatty changes 
Centrilobular steatosis, inflammation, Apoptosis, and Cell necrosis. Therefore, the 
main intercellular structures which are affected by CCl4 are Plasma membrane, 
Endoplasmic reticulum, Mitochondria, and Golgi apparatus. As a result of damaging 
the cell membrane of Hepatocytes, enzymes release in circulation. In the CCl4-
treated group, the levels of SGOT, SGPT, AP, Bilurubin, HDL reduced and the 
levels of Triglyceride, LDL and Total cholesterol increased compared to the normal 
and control group, indicating severe Hepatocellular damage. After the drug and 
extract treated group of animalsSGOT, SGPT, AP, Bilurubin, HDL increased and 
the levels of Triglyceride, LDL and Total cholesterol lowered compared to the 
normal and control group by the illustration has expressed reduction of Hepatic 
damage. 
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Table No. 7: Serum Biochemical extracts 
Groups Category Triglyceride
s (mg/dl) 
HDL 
(mg/dl) 
LDL 
(mg/dl) 
Total 
(g/dl) 
Total 
Bilirubin 
(mg/dl) 
SGOT 
(IU/L) 
SGPT 
(IU/L) 
Alkaline 
Phosphatase 
(kA units) 
I Normal Control 150.26±0.05 37.90 ±1.20 15.35±0.81 8.12±0.16 0.26±0.54 37.22±0.22 35.65±0.56 7.43±0.41 
II 
 
CCl4 270.56±0.56 
 
28.67 ±0.56 
 
57.33±1.74 4.22±0.68 1.04±0.21 110.3±0.43 83.76±0.51 25.67±0.92 
III 
Standard 
liver tonic 
+ CCl4 
 
166.67±0.56 
*** 
 
32.81±0.79 
*** 
 
38.50±0.92 
*** 
 
4.01±0.68 
*** 
 
1.00±0.31 
*** 
 
61.56±0.57 
*** 
 
39.05±0.67 
*** 
 
12.54±0.38 
*** 
IV 
Extract 
(400 
mg/kg) + 
CCl4 
 
190.23±0.58 
** 
 
26.13±0.57 
   ** 
 
23.09±0.42 
*** 
 
6.04±0.73 
** 
 
1.03±0.61 
** 
 
62.45±0.58 
*** 
 
56.22±0.46 
** 
 
13.56±0.88 
*** 
 
 The Serum levels were analysed by using kits and all values are expressed as mean ±SEM (n=6) group 2 was compared with 
group 3 were compared  with group 4; *p<0.05,**p<0.01,***p<0.001 evaluated by one way ANOVA followed by Dunnet ‘t’ test
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                                   Figure No.  15: Serum Triglyceride Level    
In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased TG Level. Where as Standard Livertonic group(III) 
significantly reduced (p<0.001) TG Levels. Similarly, the Ixora Chenensis Extract dose 
level of 400mg (p<0.001) significantly reduced when compared to Group (II). 
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Figure No. 16: Serum Cholesterol Level 
In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased SC Level. Where as Standard Livertonic group(III) 
significantly reduced (p<0.001) SCLevels. Similarly, the Ixora Chenensis Extract dose 
level of 400mg (p<0.001) significantly reduced when compared to Group(II). 
 
 
 
 
 
Chapter – 7                                             Results & Discussion 
Department of Pharmacology 56                       J.K.K. Nattraja College of Pharmacy 
T o t a l  B i l i r u b in  C h o le s t e r o l  ( m g /d l )
N o
rm
a l
 
C o
n
tr
o l
C C
l4
S t
a n
d a
rd
 
l iv
e r
 
to
n
ic  
+  
C C
l4
E x
tr
a c
t  (4
0 0
 
m
g /k
g )  
+  
C C
l4
0 .0 0
0 .2 5
0 .5 0
0 .7 5
1 .0 0
1 .2 5
1 .5 0
1 .7 5
2 .0 0
G r o u p s
T
o
ta
l B
ili
r
u
b
in
 
C
h
o
le
st
e
r
o
l (
m
g/
d
l)
 
                                    Figure No. 17: Total Bilirubin Cholesterol Level 
 In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased TBC Level When compared to Normal Control. Where 
as Standard Livertonic group(III) significantly reduced (p<0.001) TBC Levels compared 
to Group(II). The Ixora Chenensis Extract dose level of 400mg (p<0.001) significantly 
Increased when compared to Group(III). 
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                         Figure No. 18: Serum Glutamic Oxaloacetic Transaminase Level  
 
In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased SGOT Level When compared to Normal Control. 
Where as Standard Livertonic group(III) significantly reduced (p<0.001) SGOT Levels 
compared to Group(II). The Ixora Chenensis Extract dose level of 400mg (p<0.001) 
significantly Increased when compared to Group(III). 
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     Figure No. 19: Serum Glutamate-Pyruvate Transaminase 
In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased SGPT Level When compared to Normal Control. 
Where as Standard Livertonic group(III) significantly reduced (p<0.001) SGPT Levels 
compared to Group(II). The Ixora Chenensis Extract dose level of 400mg (p<0.001) 
significantly Increased when compared to Group(III). 
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Figure No. 20: Serum Alkaline Phosphatase  
In Present Study, CCL4 Induced Hepatoprotective Activity in Wistar Rat 
significantly (p<0.001) increased SKP Level When compared to Normal Control. Where 
as Standard Livertonic group(III) significantly reduced (p<0.001) SKP Levels compared 
to Group(II). The Ixora Chenensis Extract dose level of 400mg (p<0.001) significantly 
Increased when compared to Group(III). 
DISCUSSION  
 For screening the hepatoprotective drugs, liver damage is usually induced by 
CCL4. As a result there is a rise in different liver enzyme levels in serum that is SGOT, 
SGPT, TB, AP and also for cholesterol which have been recognized as a sign to the 
damaged structural integrity of the liver, because they are cytoplasmic in location and 
released into circulation after cellular damages. 
Chapter – 8                                              Conclusion 
Department of Pharmacology 60                       J.K.K. Nattraja College of Pharmacy 
8.0 CONCLUSION 
 In conclusion, from the overall result of the biochemical and histopathological 
examinations, it will be inferred that Ixora chenensis which may be have highest 
hepatoprotective activity among the four tested plant extracts.  This work will be useful 
for extended for the isolation and structure determination of the hepatoprotective 
principles. 
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